RAIN Stock Overview
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rain Oncology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.21 |
| 52 Week High | US$11.32 |
| 52 Week Low | US$0.82 |
| Beta | 0.27 |
| 1 Month Change | 0% |
| 3 Month Change | 13.08% |
| 1 Year Change | -87.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.34% |
Recent News & Updates
Recent updates
Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?
Feb 23
We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully
Nov 08Rain Therapeutics GAAP EPS of -$0.66 in-line
Aug 04Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation
Aug 03We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate
Apr 17We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth
Dec 25We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely
Sep 21Shareholder Returns
| RAIN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.6% | 0.9% | 1.2% |
| 1Y | -87.9% | 13.9% | 24.7% |
Return vs Industry: RAIN underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: RAIN underperformed the US Market which returned 18.1% over the past year.
Price Volatility
| RAIN volatility | |
|---|---|
| RAIN Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RAIN has not had significant price volatility in the past 3 months.
Volatility Over Time: RAIN's weekly volatility has decreased from 15% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 63 | Avanish Vellanki | www.rainoncology.com |
Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company’s lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022.
Rain Oncology Inc. Fundamentals Summary
| RAIN fundamental statistics | |
|---|---|
| Market cap | US$44.03m |
| Earnings (TTM) | -US$72.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs RAIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAIN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$72.26m |
| Earnings | -US$72.26m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RAIN perform over the long term?
See historical performance and comparison